People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2013 |
| Elucida Oncology, Inc. | — | Biotechnology | Series B | $117.1M | $255.3M | 2017 |
| Marina Biotech, Inc. | — | Pharmaceuticals | Series C | $69.2M | $113.7M | 2017 |
Isaac A. Blech at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Isaac A. Blech on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 2 | 14 |
| Tim Boris | 2 | 3 |
| ULI HACKSELL | 2 | 3 |
| Tim A. Boris | 2 | 2 |
| Michael Smith | 1 | 20 |
| Robert Ruffolo | 1 | 8 |
| EUGENE A. BAUER | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Sol J. Barer | 1 | 6 |
| Michael T. Smith | 1 | 5 |
| Vuong Trieu | 1 | 5 |
| R. John Fletcher | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Christopher Sullivan | 1 | 3 |
| Behshad Sheldon | 1 | 3 |
| Gary Sender | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Peter D. Parker | 1 | 3 |
| Frank A. Torti | 1 | 3 |
| Magnus Persson | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.